Oncolytic adenovirus treatment of a patient with refractory neuroblastoma

Acta Oncologica

Volumn 49, Issue 1, 2010, Pages 117-119

  Pesonen, Sari ^a,b,c   Helin, Heikki ^b,c   Nokisalmi, Petri ^a,b,c   Escutenaire, Sophie ^a,b,c   Ribacka, Camilla ^a,b,c   Sarkioja, Merja ^a,b,c   Cerullo, Vincenzo ^a,b,c   Guse, Kilian ^a,b,c   Bauerschmitz, Gerd ^a,b,c,d   Laasonen, Leena ^a   Kantola, Teemu ^b   Ristimaki, Ari ^b,c,e   Rajecki, Maria ^a,b,c   Oksanen, Minna ^a,b,c   Haavisto, Elina ^a,b,c   Kanerva, Anna ^a,b,c   Joensuu, Timo ^f   Hemminki, Akseli ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e BIOMEDICUM HELSINKI   (Finland)

^f Docrates Oncology Clinic   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; ONCOLYTIC ADENOVIRUS; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW METASTASIS; CASE REPORT; CHILD; HUMAN; LETTER; LYMPH NODE METASTASIS; MALE; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADENOVIRIDAE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY;

EID: 76649122514     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860902953864     Document Type: Letter

References (4)

1. Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 2006;14:164-74.
2. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17.
3. Alemany R. A smart move against cancer for vaccinia virus. Lancet Oncol 2008;9:507-8.
4. Prestwich R, Harrington K, Vile R, Melcher A. Immunotherapeutic potential of oncolytic virotherapy. Lancet Oncol 2008;9:610-2.